These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 21809371

  • 1. Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo.
    Alessandrino EP, Angelucci E, Cazzola M, Porta MG, Di Bartolomeo P, Gozzini A, Malcovati L, Pioltelli P, Sica S, Bosi A.
    Am J Hematol; 2011 Oct; 86(10):897-902. PubMed ID: 21809371
    [No Abstract] [Full Text] [Related]

  • 2. Iron overload and stem cell transplant-and the beat goes on.
    Tefferi A.
    Am J Hematol; 2011 Oct; 86(10):825-6. PubMed ID: 21922523
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Iron chelation therapy in myelodysplastic syndromes: we need more evidence, not more guidelines.
    Butler A, Patton WN.
    Intern Med J; 2012 May; 42(5):481-4. PubMed ID: 22616959
    [No Abstract] [Full Text] [Related]

  • 5. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.
    Steensma DP.
    Curr Hematol Malig Rep; 2011 Jun; 6(2):136-44. PubMed ID: 21373838
    [Abstract] [Full Text] [Related]

  • 6. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A, Stone RM.
    Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
    [No Abstract] [Full Text] [Related]

  • 7. Iron chelation therapy in low risk myelodysplastic syndrome.
    Killick SB.
    Br J Haematol; 2017 May; 177(3):375-387. PubMed ID: 28300275
    [Abstract] [Full Text] [Related]

  • 8. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP, Yang YS, Yao CY, Peng CT.
    Hemoglobin; 2009 May; 33(5):339-45. PubMed ID: 19814680
    [Abstract] [Full Text] [Related]

  • 9. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.
    Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, Falda M, Onida F, Bernardi M, Guidi S, Lucarelli B, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Pascutto C, Oneto R, Pirolini L, Fanin R, Bosi A.
    Haematologica; 2010 Mar; 95(3):476-84. PubMed ID: 19903678
    [Abstract] [Full Text] [Related]

  • 10. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C, Clissa C, Stanzani M.
    Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
    [Abstract] [Full Text] [Related]

  • 11. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA.
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Effects of iron chelation therapy on allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome patients with iron overload].
    Gu CH, Li CX, Ye L, Liu H, Ma JF, Wang T, Zou Q, Chen J, Chen XC, Wu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):189-93. PubMed ID: 27033754
    [Abstract] [Full Text] [Related]

  • 14. Iron chelation therapy in myelodysplastic syndromes: where do we stand?
    Mitchell M, Gore SD, Zeidan AM.
    Expert Rev Hematol; 2013 Aug; 6(4):397-410. PubMed ID: 23991926
    [Abstract] [Full Text] [Related]

  • 15. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
    Mittelman M, Lugassy G, Merkel D, Tamary H, Sarid N, Rachmilewitz E, Hershko C, MDS Israel Group, Israel Society of Hematology.
    Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
    [No Abstract] [Full Text] [Related]

  • 16. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

  • 17. Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies.
    Abraham I, Yami MA, Yun S, Kim HJ, Vincelette ND, McBride A, MacDonald K.
    Leuk Res; 2017 Jun; 57():104-108. PubMed ID: 28343141
    [No Abstract] [Full Text] [Related]

  • 18. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.
    Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR, Sill H, Bettelheim P, Pfeilstöcker M.
    Eur J Clin Invest; 2008 Mar; 38(3):143-9. PubMed ID: 18218040
    [Abstract] [Full Text] [Related]

  • 19. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
    Greenberg PL.
    J Natl Compr Canc Netw; 2006 Jan; 4(1):91-6. PubMed ID: 16403408
    [Abstract] [Full Text] [Related]

  • 20. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y.
    Blood; 2014 Aug 07; 124(6):873-81. PubMed ID: 24923296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.